Greenwich Biosciences

A drug from GW Pharmaceuticals plc (NASDAQ: GWPH) targeting a cause of genetic epilepsy has received Priority Review status from the U.S. Food and Drug Administration.  The Cambridge, U.K.-based company and its subsidiary Greenwich Biosciences Inc. confirmed Tuesday...